Answers are grounded in this paper and cite their sources.
Background Age at menopause is a clinically accessible marker of reproductive aging, but its relationship with first-onset multimorbidity during later-life follow-up remains insufficiently characterized. Methods We analyzed harmonized longitudinal data from the Health and Retirement Study (HRS), the English Longitudinal Study of Ageing (ELSA), and the Mexican Health and Aging Study (MHAS). A total of 6,576 women with an available age at menopause, no recorded hysterectomy by baseline, and zero or one of seven participant-reported physician-diagnosed chronic conditions at baseline were included. Menopause age was categorized as ≤40, 41–45, 46–49, 50–51, 52–53, and ≥54 years, with 50–51 years as the reference group. Incident multimorbidity was defined as the first follow-up assessment at which at least two of the seven conditions coexisted. Cox proportional hazards models with cohort-stratified baseline hazards were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). Results Among 6,576 women, 2,031 incident multimorbidity events occurred during 36,496.1 person-years of follow-up, with a mean follow-up of 5.55 years. In the fully adjusted pooled model, menopause at ≤40 years and 41–45 years was associated with higher risk than menopause at 50–51 years, with HRs of 1.218 (95% CI, 1.052–1.410) and 1.214 (95% CI, 1.050–1.404), respectively. Cohort-specific and sensitivity analyses generally supported the main findings. Conclusion Compared with menopause at 50–51 years, menopause at ≤40 or 41–45 years was associated with a higher risk of subsequently observed incident multimorbidity during later-life follow-up. Earlier menopausal timing may represent a useful life-course marker for identifying women at elevated risk of chronic disease accumulation in later life.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: